期刊文献+

沙利度胺在炎症性肠病治疗中的作用 被引量:1

下载PDF
导出
摘要 炎症性肠病(inflammatory bowel disease,IBD)包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn’s disease,CD),是一组反复发作的非特异性的慢性肠道炎症性疾病,最早在北欧和北美洲人群中被发现。随着我国经济快速发展,近年来,本病发病率和患病率呈逐年增加的趋势,已成为我国消化系统常见病[1,2]。随着对IBD病因研究的不断深入,其治疗方法已经从单纯的抗炎治疗发展到包括抗炎、益生菌、免疫调节等在内的综合治疗。下面就IBD的发病原因及沙利度胺在IBD治疗中的应用进行综述。
出处 《承德医学院学报》 2014年第1期59-62,共4页 Journal of Chengde Medical University
  • 相关文献

参考文献30

  • 1Wang Y, Ouyang Q.Ulcerative colitis in China:retrospective analysis of 3100 hospitalized patients[J].J Gastroenterol Hepatol,2007,22(9):1450-1455. 被引量:1
  • 2APDW 2004 Chinese IBD Working Group.Retrospective analysis of 515 cases of Crotmis disease hospitalization in China:Nationwide study from 1990 to 2003[J].Gastroenterol Hepatol,2006, 21(6):1009-1015. 被引量:1
  • 3Stallmach A,Hagel S,Bnms T.Adverse effects of biologics used for treating IBD[J].Best Pmct Res Clin Gastroenterol,2010,24(2): 167-182. 被引量:1
  • 4Gardet A,Xavier RJ.Common alleles that influence autophagy and the risk for inflammatory bowel disease[J].Curr Opin Immunol,2012,24(5):522-529. 被引量:1
  • 5Gaya DR4Rttssell RK,Nimmo ER,et al.New genes in inflammatory bowel disease:lessons for complex diseases?[J].Lancet2006,367(9 518):1271-1284. 被引量:1
  • 6Tannock GWMolecular analysis of the intestinal microflom in IBD[J].Mucosal Immunol~008, l(Suppl 1):S15-S 18. 被引量:1
  • 7张静,韩英,王继恒.炎症性肠病与肠道细菌研究进展[J].世界华人消化杂志,2007,15(12):1406-1410. 被引量:29
  • 8Macfarlane S,Steed H,Macfarlane GT.Intestinal bacteria and inflammatory bowel diaease[J]. Ctit Rev Clin Lab Sci,2009,46(1 ):25-54. 被引量:1
  • 9毛靖伟,王英德.肠黏膜屏障在炎症性肠病中作用机制的研究进展[J].世界华人消杂志,2010,18(7):695-698. 被引量:1
  • 10Shannon E,Noveek R, Sandoval F, et al.Thalidomide suppressed ILlbeta while enhancing TNF-alpha and IL-10,when cells in whole blood were stimulated with lipopoly saccharide[J]. Immunopharmacol Immunotoxicol,2008,30(3):447-457. 被引量:1

二级参考文献62

  • 1白爱平.炎症性肠病发病机制的微生物因素[J].世界华人消化杂志,2006,14(7):645-649. 被引量:28
  • 2Moss AC. Kim K J, Fernandez Becker N,et al. Impact of concomitant immunomodulator use on long term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci, 2009, Jun, 18. [Epub ahead of print]. 被引量:1
  • 3Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximah in 614 patients with Crohn's disease: results from a single centre cohort. Gut, 2009,58:192-500. 被引量:1
  • 4Schnitzler F. Fidder H, Fcrrante M, et al. Mucosal healing predicts long term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis, 2009,15: 1295-1301. 被引量:1
  • 5Hyams JS, herer T, Griffilhs A, et al. I.ong term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009,15:816-822. 被引量:1
  • 6Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn' s disease with intolerance or lost response to infliximab: a 3 year single centre experience. Aliment Pharmacol Ther, 2009,29:416-423. 被引量:1
  • 7Oussalah A, Laciotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther, 2008,28:966-972. 被引量:1
  • 8Caspersen S, Elkjaer M, Rus L, et al. Inflixirnab for inflammatory bowel disease in Denmark 1999 2005.-clinical outcome and follow up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol, 2008, 6:1212-1217. 被引量:1
  • 9Colombel JF, Loftus EV Jr, Tremaine WJ, el al. The safety profile of infliximab in patients with Crohn' s disease:the Mayo clinic experience in S00 patienls. Gastroenterology, 2004,126:19-31. 被引量:1
  • 10Russo EA, Iacucci M, Lindsay JO, et al. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol, 2009, Jun, 12. [Epub ahead of print]. 被引量:1

共引文献46

同被引文献11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部